{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:56:18Z","timestamp":1793127378483,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015791\/1"],"award-info":[{"award-number":["MR\/R015791\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015791\/1"],"award-info":[{"award-number":["MR\/R015791\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Melville Trust for the Care and Cure of Cancer Ninewells Cancer Campaign"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Maintenance PARP inhibitor (olaparib or niraparib) treatment is commonly prescribed following carboplatin\/paclitaxel chemotherapy in ovarian cancer patients, but response is compromised by adaptive drug resistance [1]. We have shown that P-gp\/\n                      <jats:italic>ABCB1<\/jats:italic>\n                      influences resistance to paclitaxel and olaparib, but similar niraparib resistance mechanisms have not been described [2, 3].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We used qRT-PCR, Western blot, RNASeq and LC-MS\/MS proteomics analysis to compare drug transporter expression in sensitive and resistant immortalised and primary patient-derived cell lines.\n                      <jats:italic>ABCB1<\/jats:italic>\n                      and\n                      <jats:italic>ABCG2<\/jats:italic>\n                      expression was modified by shRNA-mediated knockdown and heterologous expression, with chemosensitivity changes assessed by MTT and clonogenic assays. Substrate specificity of P-gp and BCRP was assessed by efflux assays in polarised cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      P-gp\/\n                      <jats:italic>ABCB1<\/jats:italic>\n                      expression was not increased in A2780nirapR cells, which alternatively up-regulated BCRP\/\n                      <jats:italic>ABCG2<\/jats:italic>\n                      .\n                      <jats:italic>ABCG2<\/jats:italic>\n                      was consistently induced in niraparib-resistant patients, but\n                      <jats:italic>ABCB1<\/jats:italic>\n                      only in patients pre-treated with paclitaxel. sh\n                      <jats:italic>ABCG2<\/jats:italic>\n                      re-sensitised A2780nirapR cells, while heterologous expression in A2780 cells induced drug resistance. Efflux assays confirmed that olaparib and niraparib are both P-gp and BCRP substrates, suggesting that resistance results from transcriptional regulation of efflux transporters not substrate specificity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Treatment-induced BCRP\/\n                      <jats:italic>ABCG2<\/jats:italic>\n                      induction is a novel clinically relevant niraparib resistance biomarker. Routine inclusion of paclitaxel in first-line chemotherapy regimens may promote efflux transporter-mediated resistance, compromising response to PARPi maintenance treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03423-z","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:46:19Z","timestamp":1776440779000},"page":"290-302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of novel drug-specific PARP inhibitor resistance mechanisms in ovarian cancer\u2013implications for clinical practice"],"prefix":"10.1038","volume":"135","author":[{"given":"Caitlin J.","family":"Macdonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"McWhirter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparajitha","family":"Vaidyanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle J.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4159-5958","authenticated-orcid":false,"given":"H. Christian","family":"Eberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euan A.","family":"Stronach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Sawers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9288-7566","authenticated-orcid":false,"given":"Gillian","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"4","key":"3423_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bcpt.13928","volume":"133","author":"F Deng","year":"2023","unstructured":"Deng F, Sistonen J, Neuvonen M, Niemi M. Inhibition of efflux transporters by poly ADP-ribose polymerase inhibitors. Basic Clin Pharm Toxicol. 2023;133(4):428\u201336.","journal-title":"Basic Clin Pharm Toxicol"},{"key":"3423_CR2","doi-asserted-by":"publisher","first-page":"116219","DOI":"10.1016\/j.bcp.2024.116219","volume":"228","author":"Y Li","year":"2024","unstructured":"Li Y, Guo F, Wang W, Lv F, Zhang L, Zhu M, et al. Marein, a novel natural product for restoring chemo-sensitivity to cancer cells through competitive inhibition of ABCG2 function. Biochem Pharm. 2024;228:116219.","journal-title":"Biochem Pharm"},{"issue":"7","key":"3423_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.tranon.2019.04.007","volume":"12","author":"AP Lombard","year":"2019","unstructured":"Lombard AP, Liu C, Armstrong CM, D\u2019Abronzo LS, Lou W, Chen H, et al. Overexpressed ABCB1 induces Olaparib-Taxane cross-resistance in advanced prostate cancer. Transl Oncol. 2019;12(7):871\u20138.","journal-title":"Transl Oncol"},{"key":"3423_CR4","volume-title":"SIGN 135: management of epithelial ovarian cancer","author":"SIGN","year":"2013","unstructured":"SIGN SIGN 135: management of epithelial ovarian cancer. Edinburgh UK: A National Clinical Guideline; 2013."},{"issue":"3","key":"3423_CR5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/cancers15030818","volume":"15","author":"F Heitz","year":"2023","unstructured":"Heitz F, Ataseven B, Staniczok C, Denkert C, Rhiem K, Hahnen E, et al. Implementing HRD testing in routine clinical practice on patients with primary high-grade advanced ovarian cancer. Cancers. 2023;15(3):818.","journal-title":"Cancers"},{"issue":"7381","key":"3423_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nature10760","volume":"481","author":"CJ Lord","year":"2012","unstructured":"Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481(7381):287\u201394.","journal-title":"Nature"},{"issue":"7035","key":"3423_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913\u20137.","journal-title":"Nature"},{"issue":"21","key":"3423_CR8","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012;72(21):5588\u201399.","journal-title":"Cancer Res"},{"issue":"7035","key":"3423_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321.","journal-title":"Nature"},{"issue":"10","key":"3423_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan S, Coward JI, Bast RC Jr., Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719\u201325.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3423_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1124\/mol.108.052381","volume":"75","author":"CA Larson","year":"2009","unstructured":"Larson CA, Blair BG, Safaei R, Howell SB. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharm. 2009;75(2):324\u201330.","journal-title":"Mol Pharm"},{"issue":"6","key":"3423_CR12","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/bjc.2014.386","volume":"111","author":"L Sawers","year":"2014","unstructured":"Sawers L, Ferguson MJ, Ihrig BR, Young HC, Chakravarty P, Wolf CR, et al. Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines. Br J Cancer. 2014;111(6):1150\u20138.","journal-title":"Br J Cancer"},{"key":"3423_CR13","first-page":"279","volume":"8","author":"D Zhang","year":"2014","unstructured":"Zhang D, Yang R, Wang S, Dong Z. Paclitaxel: new uses for an old drug. Drug Des Dev Ther. 2014;8:279\u201384.","journal-title":"Drug Des Dev Ther"},{"issue":"4","key":"3423_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0006-2952(97)83383-7","volume":"53","author":"H Parekh","year":"1997","unstructured":"Parekh H, Wiesen K, Simpkins H. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharm. 1997;53(4):461\u201370.","journal-title":"Biochem Pharm"},{"issue":"4750","key":"3423_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.3457471","volume":"232","author":"DW Shen","year":"1986","unstructured":"Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science. 1986;232(4750):643\u20135.","journal-title":"Science"},{"issue":"4","key":"3423_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/bjc.2016.203","volume":"115","author":"A Vaidyanathan","year":"2016","unstructured":"Vaidyanathan A, Sawers L, Gannon AL, Chakravarty P, Scott AL, Bray SE, et al. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 2016;115(4):431\u201341.","journal-title":"Br J Cancer"},{"issue":"7182","key":"3423_CR17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nature06548","volume":"451","author":"SL Edwards","year":"2008","unstructured":"Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451(7182):1111\u20135.","journal-title":"Nature"},{"issue":"22","key":"3423_CR18","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"25","key":"3423_CR19","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in Patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"3","key":"3423_CR20","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/bjc.2011.555","volume":"106","author":"E Dean","year":"2012","unstructured":"Dean E, Middleton MR, Pwint T, Swaisland H, Carmichael J, Goodege-Kunwar P, et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer. 2012;106(3):468\u201374.","journal-title":"Br J Cancer"},{"issue":"1-2","key":"3423_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55\u201363.","journal-title":"J Immunol Methods"},{"issue":"1","key":"3423_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57(1):289\u2013300.","journal-title":"J R Stat Soc Ser B"},{"key":"3423_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-1-0716-1024-4_17","volume":"2228","author":"T Werner","year":"2021","unstructured":"Werner T, Steidel M, Eberl HC, Bantscheff M. Affinity enrichment chemoproteomics for target deconvolution and selectivity profiling. Methods Mol Biol. 2021;2228:237\u201352.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"3423_CR24","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1021\/acs.jproteome.0c00900","volume":"20","author":"N Zinn","year":"2021","unstructured":"Zinn N, Werner T, Doce C, Mathieson T, Boecker C, Sweetman G, et al. Improved proteomics-based drug mechanism-of-action studies using 16-plex isobaric mass tags. J Proteome Res. 2021;20(3):1792\u2013801.","journal-title":"J Proteome Res"},{"issue":"7","key":"3423_CR25","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3423_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09312-9","volume":"10","author":"EL Christie","year":"2019","unstructured":"Christie EL, Pattnaik S, Beach J, Copeland A, Rashoo N, Fereday S, et al. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. Nat Commun. 2019;10(1):1295.","journal-title":"Nat Commun"},{"issue":"7553","key":"3423_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"AM Patch","year":"2015","unstructured":"Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489\u201394.","journal-title":"Nature"},{"issue":"20","key":"3423_CR28","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.4161\/cc.22026","volume":"11","author":"L Oplustilova","year":"2012","unstructured":"Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle. 2012;11(20):3837\u201350.","journal-title":"Cell Cycle"},{"issue":"7","key":"3423_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"3423_CR30","doi-asserted-by":"publisher","first-page":"9997","DOI":"10.1021\/acsomega.8b00896","volume":"3","author":"SW Reilly","year":"2018","unstructured":"Reilly SW, Puentes LN, Hsieh CJ, Makvandi M, Mach RH. Altering nitrogen heterocycles of AZD2461 affords high affinity poly(ADP-ribose) polymerase-1 inhibitors with decreased P-glycoprotein interactions. ACS Omega. 2018;3(8):9997\u201310001.","journal-title":"ACS Omega"},{"issue":"6","key":"3423_CR31","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/jps.23952","volume":"103","author":"D Lawlor","year":"2014","unstructured":"Lawlor D, Martin P, Busschots S, Thery J, O\u2019Leary JJ, Hennessy BT, et al. PARP inhibitors as P-glyoprotein substrates. J Pharm Sci. 2014;103(6):1913\u201320.","journal-title":"J Pharm Sci"},{"key":"3423_CR32","unstructured":"FDA. Zejula: highlights of prescribing information: FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/214876s000lbl.pdf.2023 (2023)."},{"key":"3423_CR33","doi-asserted-by":"publisher","first-page":"101028","DOI":"10.1016\/j.drup.2023.101028","volume":"73","author":"QX Teng","year":"2024","unstructured":"Teng QX, Lei ZN, Wang JQ, Yang Y, Wu ZX, Acharekar ND, et al. Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor. Drug Resist Updat. 2024;73:101028.","journal-title":"Drug Resist Updat"},{"issue":"12","key":"3423_CR34","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1021\/acs.molpharmaceut.1c00553","volume":"18","author":"FM ML","year":"2021","unstructured":"ML FM, Loos NHC, Mucuk S, de Jong D, Lebre MC, Rosing H, et al. P-glycoprotein (ABCB1\/MDR1) controls brain penetration and intestinal disposition of the PARP1\/2 inhibitor niraparib. Mol Pharm. 2021;18(12):4371\u201384.","journal-title":"Mol Pharm"},{"key":"3423_CR35","doi-asserted-by":"publisher","first-page":"106177","DOI":"10.1016\/j.ejps.2022.106177","volume":"173","author":"YK Song","year":"2022","unstructured":"Song YK, Kim MJ, Kim MS, Lee JH, Chung SJ, Song JS, et al. Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice. Eur J Pharm Sci. 2022;173:106177.","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"3423_CR36","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.3390\/pharmaceutics14122571","volume":"14","author":"M Makrecka-Kuka","year":"2022","unstructured":"Makrecka-Kuka M, Vasiljeva J, Dimitrijevs P, Arsenyan P. Olaparib conjugates with selenopheno[3,2-c]quinolinone inhibit PARP1 and reverse ABCB1-related multidrug resistance. Pharmaceutics. 2022;14(12):2571.","journal-title":"Pharmaceutics"},{"issue":"3","key":"3423_CR37","doi-asserted-by":"publisher","first-page":"189346","DOI":"10.1016\/j.bbcan.2025.189346","volume":"1880","author":"J Tan","year":"2025","unstructured":"Tan J, Zheng B, Zhou S. Deciphering the \u201cRosetta Stone\u201d of ovarian cancer stem cells: opportunities and challenges. Biochim Biophys Acta Rev Cancer. 2025;1880(3):189346.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"22","key":"3423_CR38","first-page":"3497","volume":"18","author":"HC Yan","year":"2014","unstructured":"Yan HC, Fang LS, Xu J, Qiu YY, Lin XM, Huang HX, et al. The identification of the biological characteristics of human ovarian cancer stem cells. Eur Rev Med Pharm Sci. 2014;18(22):3497\u2013503.","journal-title":"Eur Rev Med Pharm Sci"},{"issue":"3","key":"3423_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1124\/mol.114.096065","volume":"87","author":"KA Jung","year":"2015","unstructured":"Jung KA, Choi BH, Kwak MK. The c-MET\/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP\/ABCG2 expression. Mol Pharm. 2015;87(3):465\u201376.","journal-title":"Mol Pharm"},{"key":"3423_CR40","doi-asserted-by":"publisher","first-page":"620907","DOI":"10.3389\/fonc.2021.620907","volume":"11","author":"L Yin","year":"2021","unstructured":"Yin L, Yang Y, Zhu W, Xian Y, Han Z, Huang H, et al. Heat shock protein 90 triggers multi-drug resistance of ovarian cancer via AKT\/GSK3\u03b2\/\u03b2-catenin signaling. Front Oncol. 2021;11:620907.","journal-title":"Front Oncol"},{"issue":"2","key":"3423_CR41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/1878-0261.12419","volume":"13","author":"M He","year":"2019","unstructured":"He M, Wu H, Jiang Q, Liu Y, Han L, Yan Y, et al. Hypoxia-inducible factor-2\u03b1 directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin. Mol Oncol. 2019;13(2):403\u201321.","journal-title":"Mol Oncol"},{"issue":"20","key":"3423_CR42","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO-25-00007","volume":"43","author":"R Garje","year":"2025","unstructured":"Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM, et al. Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update. J Clin Oncol. 2025;43(20):2311\u201334.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3423_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","volume":"44","author":"A Jain","year":"2025","unstructured":"Jain A, Barge A, Parris CN. Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms. Oncogene. 2025;44(4):193\u2013207.","journal-title":"Oncogene"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03423-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03423-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03423-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:02:20Z","timestamp":1782705740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03423-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7,20]]}},"alternative-id":["3423"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03423-z","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Dundee Ovarian Cancer Study (DOCS) was approved by the East of Scotland Research Ethics Service REC1 Committee (13\/ES\/0035). Informed consent was obtained from all participants, and the study performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"HCE and ES are employees and shareholders of GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}